Background: A causal relationship exists between HBV infection and membranous nephropathy. The association is especially close in Black children in sub-Saharan Africa. Interferon-α2b is commonly used to treat this condition, but is effective in only 30-40% of patients. The reason for the poor response is unknown. The objective of this study was to determine if mutations in the surface gene of HBV isolated from Black children with HBV-associated membranous nephropathy before, during and after interferon treatment, have any effect on treatment response and vice versa. Methods: HBV DNA was extracted from a responder, a reverter and a non-responder before and after initiation of 16 weeks of interferon-α2b treatment. The preS1/ preS2/S region was amplified, cloned and sequenced. Results: The preS2 region was the most variable in the reverter and the non-responder, and the S region was the most variable in the non-responder. Phylogenetic analysis showed that the viral population dynamics between the responder and the reverter/non-responder strains differed as a result of mutations in the surface gene. Conclusions: The presence of mutations in the S region of HBV could be used as predictive markers to differentiate interferon-α2b responders from non-responders provided that detailed analysis of further genomes confirms our findings.
Membranous nephropathy (MN) is an uncommon but important complication of chronic HBV infection. It occurs particularly in children [1, 2] . HBV infection is endemic in the adult Black population of South Africa [3] and prior to the introduction of HBV vaccination in 1995, HBV-induced MN was commonly seen here in Black children [4] .
Although an effective and safe vaccine is now available for the prevention of HBV infection [5] and its use has already reduced the incidence of HBV-associated MN [6] , drug treatment is the only option for those already infected. Interferon (IFN)-α, a naturally occurring cytokine [7] with antiviral, antiproliferative and immunomodulatory effects [8] , was the first approved agent for the treatment of chronic HBV infection. Its efficacy is limited, however, particularly in children. IFN-α treatment of chronic HBV infection in children in western countries leads to a loss of HBV DNA or hepatitis B e antigen (HBeAg) seroconversion in 20-58% as compared with 8-17% in controls [9] [10] [11] . Success rates are lower in southeast Asian countries, where the majority of HBV-infected children are perinatally infected; only 3-17% clear HBV DNA or lose HBeAg [12] .
Although HBV is endemic in sub-Saharan Africa, only a limited number of studies have been carried out to determine the efficacy of IFN-α treatment of HBV infection in this region [13, 14] . In an earlier study [15] , IFN-α was used to treat 19 Black children with HBVassociated MN. At 40 weeks of follow-up, 10 (52.6%) patients had cleared HBeAg (responders), 4 (21.1%) had cleared HBeAg during treatment but then reverted to being HBeAg-positive (reverters) and 5 (31.6%) patients failed to clear HBeAg (non-responders). None cleared hepatitis B surface antigen (HBsAg).
The molecular and virological factors that contribute to the responsiveness of HBV infection to IFN-α treatment Introduction are largely unknown. Because IFN-α treatment is expensive, is administered by injection, can have side effects and is poorly tolerated, the ability to predict responsiveness is important in the clinical setting. To date, the most important viral factor that has convincingly been shown to determine the response to IFN-α is the pretreatment HBV DNA titre; the lower the titre, the better the response [16, 17] . The genotypes of HBV can also influence the response to IFN-α [18] , with genotypes A and B responding better than D and C, respectively [19] . Although a number of studies have been carried out to determine the influence of viral sequence heterogeneity on IFN-α response [17, [20] [21] [22] , none have been within the South African context and it was therefore decided to take advantage of the specimens available from the previous study on Black children with HBVassociated MN treated with IFN-α [15] . Considering that the majority of South African HBV isolates belong to subgenotype A1, which has unique sequence characteristics [23] , studies on patient response from other countries, where other genotypes prevail, cannot necessarily be directly extrapolated to this subgenotype. Although some studies showed that basic core promoter mutations play a role in response to IFN-α therapy [17] , other studies concluded that the basis of non-response or relapse did not lie in the catalytic domains of the polymerase gene, basic core promoter, precore and core regions and must reside in other parts of the HBV genome [22] . The surface gene might therefore be a suitable candidate for predicting patient response to IFN-α because the preS sequence, particularly the preS2 region, contains the highest heterogeneity over the entire genome [24] . The aim of the present study was to determine whether differences in the preS1/preS2/S open reading frame of HBV isolated from IFN-α2b-treated patients [15] could account for the variation in response to treatment.
Methods

Participants and serum samples
A total of 19 Black children recruited from the Renal Clinic at the King Edward VIII Hospital (Durban, South Africa) were studied. All participants had the nephrotic syndrome diagnosed in accordance with the standard criteria [25] and had been seropositive for HBsAg and HBeAg for a minimum period of 6 months before entry into the study. Clinical examination and appropriate investigations were performed to exclude other secondary causes of the nephrotic syndrome [15] . HBV, HCV and HIV status were determined as described previously [15] . The protocol was approved by the Biomedical Research Ethics Committee (University of KwaZulu-Natal, Durban, South Africa) and informed consent was obtained from the parent or guardian for entry into the study. Approval was also obtained from the University of the Witwatersrand Human Research Ethics Committee (Johannesburg, South Africa), for the testing of the serum samples in the Faculty of Health Sciences.
IFN-α2b treatment
A prospective open-labelled study of the use of IFN-α2b in these children was performed during the period of April 1997 to June 1999. IFN-α2b (Intron A; SheringPlough Co., Kenilworth, NJ, USA) in a dose of 10 million units/m 2 (maximum 10 million units/dose) was administered subcutaneously 3× per week by trained healthcare professionals to all study participants as described previously [15] . Outcome measures included HBV status, clinical criteria and biochemical assessment of renal and hepatic function [15] .
DNA extraction and amplification
Total DNA was extracted from patient sera using the QIAamp ® DNA Blood Mini kit (Qiagen, GmbH, Hilden, Germany) as per the manufacturer's instructions. When the viral concentration was high enough, the complete HBV genome was amplified using primers P1 5′-TTTTTCACCTCTGCCTAATCA-3′ (1821-1843 nucleotides from the EcoRI site of a reference sequence [GenBank number AY233276]) and P2 5′-AAAAAGTTGCATGGTGCAGG-3′ (1825-1806 nucleotides from the EcoRI site) [26] . For samples with lower viral loads, a nested PCR was used to amplify the preS1/S2/S region of HBV, with outer primers 2408 (+) 5′-TCTCAATCGCCGCGTCGCAGAAGATCTCAA-3′ (2408-2438 nucleotides from the EcoRI site) and 1327R (-) 5′-CGATGAGTTTTGCTCCAGACCGGC TGC-3′ (1327-1301 nucleotides from the EcoRI site) and inner primers 2800 (+) 5′-CACGTAGCGCATC ATTTTGCGGGTCACCATATTCT-3′ (2800-2834 nucleotides from the EcoRI site) and 1011R (-) 5′-C AAAAGACCACAATTCTTTGACATACTTTCCAA T-3′ (1011-977 nucleotides from the EcoRI site), as described previously [27] .
Cloning, genotyping, subgenotyping and sequencing
Amplicons were cloned into a pCR ® -XL-TOPO ® vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Using restriction fragment length polymorphism, HBV clones were genotyped [28] and subgenotyped [29] . The positive clones containing the correct size amplicons were prepared for direct sequencing using the BigDye Terminator version 3.0 Cycle Sequencing Ready Reaction kit (Applied Biosystems, Inc., Foster City, CA, USA) and sequenced on a 377 DNA automated sequencer (Applied Biosystems, Inc.) using vector-specific primers T3 (5′-AATTAACCCTCACTAAAGGG-3′) and T7 (5′-GTAATACGACTCACTATAGGGC-3′) as well as HBV-specific primers [27] . All sequences were analysed in both the forward and reverse directions. Nucleotide and amino acid divergences were calculated using Data Analysis in Molecular Biology and Evolution software [30] .
Phylogenetic analyses
Complete surface gene sequences from a responder, a reverter and a non-responder were compared with corresponding sequences of HBV from GenBank as described previously [23] .
Results
Serum samples from a responder, a reverter and a nonresponder to 16-week IFN-α2b treatment were randomly selected and HBV DNA extracted. All children had high HBV DNA levels on commencement of treatment (>2×10 6 genomes/ml) [15] . The responder showed a decrease in HBV DNA levels at 40 weeks and the levels were unchanged in the non-responder. The reverter showed a decrease in HBV DNA levels at 16 weeks but reverted to pretreatment levels after the cessation of treatment [15] . Full genome amplification of the non-responder and surface gene amplification of the responder and reverter were carried out at time points before (T0), during (T2 and T4; 4 and 16 weeks after the initiation of treatment, respectively) and after treatment (T6; at 40 weeks, that is, 24 weeks after cessation of the 16-week treatment). A range of 3-10 clones were analysed for each time point and all the 93 clones analysed were found to belong to subgenotype A1 with serological subtype adw2.
The nucleotide (Table 1 ) and amino acid (Table 2 ) divergences of the clones compared with a reference sequence closest to the subgenotype A1 consensus sequence, AY233274 (GenBank accession number), were calculated. For all patients, at all time points, the most variable region was the preS2, whereas HBsAg was the most conserved at both the nucleotide and amino acid levels. The responder showed the lowest variation within preS2, whereas the reverter showed the highest divergence in the preS2 and the lowest divergence within the S gene. The non-responder showed the highest amino acid divergence within the HBsAg, whereas the amino acid divergence of the entire S region (preS1, preS2 and HBsAg) remained constant over time. The amino acid divergence of the responder and reverter, however, varied between the different time points, demonstrating the emergence of new populations over the course of therapy. For the responder and the reverter, clones from T4 displayed the highest amino acid divergences.
The phylogenetic trees of the HBV strains from the responder, the reverter and the non-responder at the different times of sampling reflected the trends described above (Figure 1 ). Before treatment (T0), the isolates formed distinct clusters, with strains from each patient clustering together. The strains of the reverter and the non-responder were the most similar, clustering together and sharing the same root. At T2, the responder and the non-responder kept the same clusters as at T0; however, the reverter separated into two clusters with separate roots, demonstrating the emergence of an additional quasispecies population. At T4, the responder clustered into two distinct populations. Within the strains of the reverter, a completely new population emerged as shown by the two distinct clusters, even more separate from those at T2. In the non-responder, a new population also emerged distinct from that at T0 and T2. At T6, the new populations within the responder, the reverter and the non-responder disappeared and the original populations present at T0 re-emerged.
All clones of HBV isolates had amino acid residues in the preS1/preS2/S regions that are characteristic of subgenotype A1 [23] . In comparison to the reference sequence, AY233274, various missense mutations were observed in the HBV from the responder, the reverter and the non-responder (Figure 2 and Table 3 ). These included Q54H in the preS1, L32H in the preS2 and M133T, D144G, E164G and L186P in HBsAg found in the dominant HBV population of the responder. None of these mutations were found in the non-responder. L32H was found in 100% of clones of the responder at T0, T2 and T6, and decreased to 40% at T4. At T4, with the separation of the responder strains into distinct clusters (Figure 1 ), there was a decrease of Q54H and L32H, the emergence of Q10R and the disappearance of E164G and L186P. This variation in amino acids at T4 accounted for the emergence of new viral populations. At all time points, Q10R and Q10K in preS2 were dominant in the reverter and the non-responder, respectively. At T2, there was a separation of the reverter strains into two clusters and the emergence of a G112R mutation, which also emerged in the non-responder following treatment. At T4, there was a further splitting of the populations and the emergence of the M133T, also found in the responder, thus explaining why these HBV isolates cluster together at T4 (Figure 1 ).
Discussion
All HBV clones, at all time points, regardless of IFNα2b response of the patient, belonged to subgenotype A1 and serological subtype adw2; therefore, differences in IFN-α2b treatment response were not a consequence of genotype or serotype diversity of the HBV obtained from the different patients.
HBV replicates by reverse transcription of the pre-genomic RNA using a polymerase that lacks proofreading ability [31] . HBV therefore exists in infected individuals as a population of phylogenetically related variants or quasispecies [32] , with one strain dominating. In order to maintain the stability of the pool, certain selection pressures from the host's immune system, constraints imposed upon by the reading frames, and the viability and replication competence of the virus need to remain intact [33] ; thus, the interaction between viral and host factors, as well as external pressures, determine the dominant HBV population [33] . However, with the introduction of IFN-α2b treatment, the balance might be disrupted, leading to the emergence of mutant HBV strains that are able to withstand therapy and leading to a non-responsive outcome. Quasispecies have been implicated in failure of vaccines and antiviral therapies [34] .
The amino acid divergences of the S open reading frame of HBV from the different patients (Table 2 ) are in agreement with other studies [35, 36] , with the preS2 being the most variable and HBsAg the most conserved. This is to be expected because the preS2 protein is not essential for HBV replication, morphogenesis, secretion or infectivity [37] , whereas HBsAg is essential in the viral life cycle [38] . The highest divergence in preS2 was seen in HBV from the reverter and the non-responder, with the highest divergence in HBsAg from the nonresponder (Tables 1 and 2 ). Because the preS region has been implicated in immunity and protection [39] , this high amino acid divergence might be responsible for persistence of HBV and non-response to IFN-α2b. The responder strains clustered separately from the non-responder/reverter strains at T0 (Figure 1 ). In the responder, an HBV strain that might have IFN-α2b treatment escape mutations persisted at all time points. In the reverter, a new population emerged that clustered in the same branch as the responder strains at T2 and T4. A new strain that clustered with the isolates from the non-responder and reverter emerged in the responder at T4, with the original strains re-emerging after the termination of treatment in all patients. Thus, all three patients demonstrated a heterogeneous HBV population, able to mould itself to the selective pressure applied by the immune system as a result of IFNα2b therapy. IFN-α2b treatment is known to increase the host immune elimination pressure on HBV-infected cells and to result in the selection of HBV quasispecies [22] . IFN-α2b treatment therefore seems to be altering the balance within the HBV quasispecies pool and selecting a mutant population able to withstand the treatment. The reason for this might be that the major population is more susceptible to IFN-α2b than the minor strains; thus, allowing IFN-α2b to enhance the immune response toward the major strain and allowing the levels of the minor strain to increase [40] . Q54H in preS1, found only in the responder, is not characteristic of subgenotype A1 or any other genotype [23] and might differentiate the HBV isolates from the responders and the non-responders. Replacing glutamine (a polar amide with high flexibility) with histidine (a polar, positively-charged amino acid containing an imidazole ring) changes the flexibility and hydrophobicity of the protein at this point, possibly altering its antigenicity. Q54H has been described in asymptomatic HBV carriers with low viral loads [41] . A unique subgenotype A1 determinant at position 32 of preS2 is characterized by leucine in the majority of subgenotype A1 isolates [23] . L32H, found only in isolates from the the responder and the reverter but not from the non-responder and in previous studies in a minority of subgenotype A1 isolates [23] , might render the virus susceptible to IFN-α2b treatment. M133T within the 'a' determinant was found in the responder and the reverter. The replacement of a non-polar hydrophobic amino acid with a polar hydrophilic amino acid would affect both the tertiary structure and hydrophobicity of the protein. Although M133 has been shown to be required for infectivity of HDV [42] , functional studies have shown enhanced HBsAg secretion and virion secretion associated with M133T [43] ; therefore, the increased fitness might explain the survival and persistence of HBV in both the responder and the reverter. Two more mutations, D144G and E164G, were also found in or near the 'a' determinant in both the responder and the reverter. They represent novel mutations and might interfere with the recognition of HBsAg by antibodies. Substitution of either of these residues with alanine has been shown to reduce antigenicity of HDV particles [42] . E164D is a lamivudine escape mutant [44] . L186P, within the immunodominant epitope for B-cell recognition (amino acids 178-186), disappeared following IFN-α2b treatment (Table 3) , possibly as a result of negative selection induced by the immune response [45] . L186 is essential for the epitope reactivity [46] . Because Q10R and Q10K are within the major preS2 antigenic epitope region, known to carry numerous B-cell, T-helper cell and cytotoxic T-lymphocyte epitopes [47] , they might be reducing the ability of IFN-α2b-induced antibodies to bind to the epitopes and initiate their neutralizing effect [46] . These mutations might be providing a survival advantage within the IFN-α2b environment leading to non-response in these patients. Occurring in clones of the reverter and the non-responder at T2 and T4, G112R probably developed as a result of this highly immunogenic region being under selective pressure from the immune system [48] and might therefore be playing a role in IFN-α2b resistance.
Contrary to other studies on different genotypes [49] , in the present study, the viral population dynamics b The numbers in the brackets indicate the percentage of clones with mutations at baseline (T0) and after 4 weeks (T2), 16 weeks (T4) and 40 weeks (T6) of initiation of interferon-α2b treatment. c The number of clones sequenced for the responder was 10, 10, 5 and 8 for T0, T2, T4 and T6, respectively. The total number of clones sequenced for the responder was 33. d Mutations found in the responder and the reverter. e Mutations found in the responder and non-responder. f The number of clones sequenced for the reverter was 9, 8, 4 and 6 for T0, T2, T4 and T6, respectively. The total of clones sequenced for the reverter was 27. g Mutations found in the reverter and the non-responder. h The number of clones sequenced for the non-responder was 10, 0, 3 and 10 for T0, T2, T4 and T6, respectively. The total number of clones sequenced for the reverter was 33. HBsAg, hepatitis B surface antigen.
Number of clones with mutation, n (%) differed between the responder and the non-responder/ reverter strains. Further research, with more cases and patients with different clinical manifestations of HBV infection, as well as functional studies, are therefore needed to determine whether these observations are pertinent only to this study or whether it might be a more generalized phenomenon that might provide us with a predictive tool for IFN-α2b treatment of patients infected with HBV.
